VA-REGULA
5.6.2024 08:31:32 CEST | Business Wire | Press release
Access to international festivals like Sziget and Untold, which draw up to 100,000 visitors daily, has been significantly enhanced. Regula, a global developer of forensic devices and identity verification solutions, and Netpositive, a Hungarian IT service provider specializing in large-scale event management, joined forces to switch to mobile ID verification (IDV) via a special app empowered by IDV software. As a result, Netpositive’s state-of-the-art Backstage Ticketing ecosystem has become an even more valuable asset for event organizers across the world.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240604833546/en/
Netpositive’s new Backstage Ticketing solution for large events’ visitor ID verification based on Regula Document Reader SDK (Graphic: Business Wire)
The backbone of access services to large-scale events is the so-called “redemption” process, during which visitor tickets are checked and exchanged for wristbands with designated access rights. For this process to function properly, it is necessary to identify event visitors by their identity documents.
Netpositive used to handle document verification with the help of designated ID scanners provided by a third-party vendor. Apart from that, the company also employed a range of other devices, such as barcode readers, NFC readers, and laptops. The complexity of managing these devices often led to inefficiencies at event redemption points.
To make the process more productive and streamlined, Netpositive decided to switch to mobile ID verification (IDV) via a special app empowered by IDV software. After performing extensive research and following a partner’s recommendation, Netpositive opted for Regula Document Reader SDK, a comprehensive identity document verification software solution. Within one month, Regula’s solution was seamlessly built into Netpositive’s Backstage Ticketing Access Management App and integrated into their larger ecosystem, where they manage everything from ticket sales to redemption checks to event dashboards.
Regula Document Reader SDK allows Netpositive’s Backstage Ticketing ecosystem to read and verify passports, ID cards, and driver’s licenses with a single mobile device. Not only does Regula’s solution speed up the document check process, but it also enhances security by performing cross-checks to identify any data discrepancies that could indicate fraud. Apart from that, Regula Document Reader SDK re-verifies biometric documents on the server side in the customer’s secure perimeter in order to ensure that the chip is genuine and its data has not been cloned or manipulated, and thus prevent sophisticated fraud. The solution's extensive document template database includes over 13,900 templates from 249 countries and territories, ensuring comprehensive coverage and seamless processing for international event attendees.
Implementing Regula’s technology has already shown remarkable success at recent events, such as Untold Dubai, visited by over 185,000 people, and Massif in Romania, with a capacity of 12,000 people per day. The streamlined mobile solution has reduced queues, cut down manual labor, and received overwhelmingly positive feedback from staff and attendees alike.
In the long run, Netpositive expects to cut expenses on device procurement, and expects to significantly reduce the number of technical problems involved with the redemption process, which were relatively frequent with the previous solution.
“We are still at an early stage of the access admission process transformation, and we assume we will get more tangible results during the coming season of summer festivals. But we are very sure of one thing: with this new solution with the Regula Document Reader SDK at the core, we made a real innovation. The reinvention of the redemption process helped us become more competitive, promoting our position in the market,” says Mátyás Török, Netpositive’s founder and CEO.
"Our collaboration with Netpositive not only showcases the importance of robust and efficient identity verification, but also sets a new standard for access management in large-scale events. We are proud to contribute to creating safer and more efficient event experiences around the globe," says Ihar Kliashchou, Chief Technology Officer at Regula.
For more information on how Netpositive is transforming event access management with Regula’s IDV solutions, read the success story.
About Netpositive
Netpositive creates large-scale, unique, load-proof digital solutions. With more than 50 partners, 500 international events, and 36 million unique users, it became Central Europe's leading event IT service provider during the last 10 years. You can meet its staff and its self-developed Backstage Ticketing ecosystem at several domestic and international events, including award-winning music festivals like Sziget (HU) and Untold (RO).
Learn more at www.netpositive.hu.
About Regula
Regula is a global developer of forensic devices and identity verification solutions. With our 30+ years of experience in forensic research and the largest library of document templates in the world, we create breakthrough technologies in document and biometric verification. Our hardware and software solutions allow over 1,000 organizations and 80 border control authorities globally to provide top-notch client service without compromising safety, security or speed. Regula was repeatedly named a Representative Vendor in the Gartner® Market Guide for Identity Verification.
Learn more at www.regulaforensics.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240604833546/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 16:00:00 CEST | Press release
IB SmartRouting℠ Routes Orders to the Best Available Price Between KRX and Nextrade Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
